Date Type Case No Country HUN 3/2011 21/12/2011 Hungary JAL Mandate(s) Summary of the allegation transmitted Reply Adequate housing; Extreme poverty; 21/02/2012 Alleged threat of mass criminalization, evictions and incarceration of homeless population in Hungary following the adoption of several amendments to national and municipal legislation. According to the information received, amendment to Act 1997/LXXVII on the transformation and protection of urban environment and to Act 1996 XXI on territorial development and settlement, adopted in October 2010, defines the various functions of public spaces and empowers municipalities to criminalize any use of public space which is not in accordance with these functions. Law Act CLIII (adopted on 14 November 2011, and entered into force on 1 December 2011), states (Article 146/A), that a person repeatedly violating municipality regulations regarding the use of public spaces for habitual living, or the storage of movable properties on public places for the purposes of habitual living, can be punished with imprisonment or up to 150,000 Hungarian forints fine. Based on these amendments, during October 2011, Budapest police allegedly evicted homeless persons from 13 underpasses in the inner city and demolished dozens of homeless self-made shelters in various parts of the city. Allegedly, the evicted persons were not provided with alternative shelter options and some of the evicted persons were subject to short term arrest. MEX 25/2011 21/12/2011 México AL Health; Se alega la supuesta falta de ensayos clínicos adecuados para la aprobación del medicamento “Kikuzubam”. Según informaciones recibidas, la Comisión Federal para la Protección de Riesgos Sanitarios (COFEPRIS) de la Secretaría de la Salud, habría otorgado la autorización de comercialización del medicamento "Kikuzubam", producido por la compañía farmacéutica Probiomed, S.A. de C.V. (Probiomed), sin haber obtenido los ensayos concluyentes de Probiomed con respecto a las características del medicamento a nivel de calidad, como por ejemplo: los ensayos pre-clínicos, los ensayos clínicos, los estudios de inmunogenicidad y la información de farmacovigilancia antes de conceder la autorización. A/HRC/20/30 25